<p>Marex Group plc 在第二季度购买了 TG Therapeutics, Inc. (NASDAQ:TGTX - 免费报告) 的新股份，根据该公司最近向证券交易委员会提交的 13F 文件。该公司购买了 278,316 股生物制药公司的股票，价值约为 10,017,000 美元。Marex Group plc 在最近的报告期末持有 TG Therapeutics 约 0.18% 的股份。</p>
<ul>
<li>六月最被做空的股票：持有、做空还是挤压？</li>
</ul>
<p>其他一些机构投资者最近也对该公司的持仓进行了调整。Ameritas Advisory Services LLC 在第二季度获得了 TG Therapeutics 的新头寸，价值 25,000 美元。Johnson Financial Group Inc. 在第二季度购买了 TG Therapeutics 的新股份，价值 25,000 美元。SVB Wealth LLC 在第一季度购买了 TG Therapeutics 的新股份，价值 37,000 美元。Private Wealth Asset Management LLC 在第二季度获得了 TG Therapeutics 的新股份，价值约 37,000 美元。最后，EverSource Wealth Advisors LLC 在第二季度将其在 TG Therapeutics 的股份增加了 86.3%。EverSource Wealth Advisors LLC 现在拥有 1,237 股生物制药公司的股票，价值 45,000 美元，此前在上个季度又购买了 573 股。58.58% 的股票由机构投资者和对冲基金持有。</p>
<p>获取 <strong>TG Therapeutics</strong> 警报：</p>
<h2>华尔街分析师意见</h2>
<p>几位分析师最近对该股票发布了报告。B. Riley 在 11 月 4 日的研究报告中将 TG Therapeutics 的股票评级提高至 &#34;强力买入&#34;。Wall Street Zen 在周日的研究报告中将 TG Therapeutics 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;。HC Wainwright 在 10 月 6 日的报告中开始覆盖 TG Therapeutics。他们对该公司发布了 &#34;买入&#34; 评级，并设定了 60.00 美元的目标价。摩根大通将 TG Therapeutics 的目标价从 46.00 美元上调至 49.00 美元，并在 11 月 3 日的研究报告中给予该股票 &#34;超配&#34; 评级。最后，Weiss Ratings 在 12 月 8 日的报告中重申了对 TG Therapeutics 股票的 &#34;持有 (c+)&#34; 评级。一位股票研究分析师对该股票给予了强力买入评级，两位给予了买入评级，两位给予了持有评级。根据 MarketBeat.com 的数据，TG Therapeutics 当前的平均评级为 &#34;适度买入&#34;，共识目标价为 50.25 美元。</p>
<ul>
<li>TG Therapeutics 股票 300% 的反弹还有潜力</li>
</ul>
<p><strong>获取我们对 TG Therapeutics 的最新分析</strong></p>
<h2>TG Therapeutics 的内部交易</h2>
<p>在其他 TG Therapeutics 的新闻中，董事 Yann Echelard 在 11 月 24 日的交易中出售了 5,000 股公司的股票。该股票以平均价格 32.57 美元出售，总价值为 162,850.00 美元。交易后，该董事持有 223,816 股公司的股票，价值 7,289,687.12 美元。这代表了他们持有股票的比例下降了 2.19%。该交易已在向 SEC 提交的文件中披露，文件可通过此链接获取。公司内部人士持有公司股票的 10.64%。</p>
<h2>TG Therapeutics 股票下跌 2.0%</h2>
<p>TGTX 周五开盘价为 31.35 美元。该股票的市值为 49.8 亿美元，市盈率为 11.28，贝塔值为 2.01。TG Therapeutics, Inc. 的一年最低价为 25.28 美元，一年最高价为 46.48 美元。该公司的债务与股本比率为 0.40，速动比率为 2.89，流动比率为 3.82。该公司的 50 日移动平均价格为 32.91 美元，200 日移动平均价格为 33.67 美元。</p>
<p>TG Therapeutics (NASDAQ:TGTX - 获取免费报告) 最近在 11 月 3 日发布了其财报。这家生物制药公司报告本季度每股收益为 2.43 美元，超出分析师共识预期的 0.24 美元，超出幅度为 2.19 美元。TG Therapeutics 的股本回报率为 133.24%，净利润率为 84.13%。该公司本季度的收入为 1.6171 亿美元，而共识预期为 1.5212 亿美元。在去年同期，该公司的每股收益为 0.02 美元。该公司的季度收入同比增长 92.7%。作为一个整体，股票研究分析师预计 TG Therapeutics, Inc. 本年度将发布 0.08 美元的每股收益。</p>
<h2>TG Therapeutics 公司简介</h2>
<p>(免费报告)</p>
<p>TG Therapeutics, Inc. 是一家商业阶段的生物制药公司，专注于在美国和国际上获取、开发和商业化针对 B 细胞介导疾病的新疗法。它提供 BRIUMVI，一种抗 CD20 单克隆抗体，用于治疗成人复发性多发性硬化症 (RMS) 患者，包括临床孤立综合症、复发 - 缓解型疾病和活动性继发进展型疾病的成人患者。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过 TG Therapeutics</li>
<li>什么是分红成就者？简介</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
<li>5 个适合分红增长投资者的折扣机会</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>如何从价值投资中获利</li>
<li>Adobe 在财报后获得提振：长期前景看涨</li>
</ul>
<p><strong>想看看其他对冲基金持有 TGTX 吗？</strong> 访问 HoldingsChannel.com 获取 TG Therapeutics, Inc. (NASDAQ:TGTX - 免费报告) 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEdUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEdUWA"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 TG Therapeutics 吗？</h2>
<p>在考虑 TG Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议他们现在购买，以便在更广泛的市场注意到之前……而 TG Therapeutics 并不在名单上。</p>
<p>虽然 TG Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TG治疗

<p>Marex Group plc 在第二季度投资了 1002 万美元于 TG Therapeutics, Inc.，收购了 278,316 股。这项投资代表了 TG Therapeutics 0.18% 的股权。其他机构投资者也调整了他们在该公司的持仓。TG Therapeutics 收到了分析师的多种评级，市场共识目标价为 50.25 美元。该公司报告了强劲的季度收益，收入和净利润率显著增长。TG Therapeutics 专注于治疗 B 细胞介导的疾病</p>

<p>Marex Group plc bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm bought 278,316 shares of the biopharmaceutical company's stock, valued at approximately $10,017,000. Marex Group plc owned approximately 0.18% of TG Therapeutics at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Marex Group plc 在第二季度购买了 TG Therapeutics, Inc. (NASDAQ:TGTX - 免费报告) 的新股份，根据该公司最近向证券交易委员会提交的 13F 文件。该公司购买了 278,316 股生物制药公司的股票，价值约为 10,017,000 美元。Marex Group plc 在最近的报告期末持有 TG Therapeutics 约 0.18% 的股份。</p>
</div><ul>
<li>The Most Shorted Stocks in June: Hold, Short, or Squeeze?</li>
</ul>
<div class="lb-trans"><ul>
<li>六月最被做空的股票：持有、做空还是挤压？</li>
</ul>
</div><p>A number of other institutional investors have also recently made changes to their positions in the company. Ameritas Advisory Services LLC acquired a new position in TG Therapeutics in the 2nd quarter valued at $25,000. Johnson Financial Group Inc. purchased a new stake in shares of TG Therapeutics during the second quarter worth $25,000. SVB Wealth LLC purchased a new stake in shares of TG Therapeutics during the first quarter worth $37,000. Private Wealth Asset Management LLC acquired a new stake in shares of TG Therapeutics in the second quarter valued at about $37,000. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of TG Therapeutics by 86.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 573 shares in the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也对该公司的持仓进行了调整。Ameritas Advisory Services LLC 在第二季度获得了 TG Therapeutics 的新头寸，价值 25,000 美元。Johnson Financial Group Inc. 在第二季度购买了 TG Therapeutics 的新股份，价值 25,000 美元。SVB Wealth LLC 在第一季度购买了 TG Therapeutics 的新股份，价值 37,000 美元。Private Wealth Asset Management LLC 在第二季度获得了 TG Therapeutics 的新股份，价值约 37,000 美元。最后，EverSource Wealth Advisors LLC 在第二季度将其在 TG Therapeutics 的股份增加了 86.3%。EverSource Wealth Advisors LLC 现在拥有 1,237 股生物制药公司的股票，价值 45,000 美元，此前在上个季度又购买了 573 股。58.58% 的股票由机构投资者和对冲基金持有。</p>
</div><p>Get <strong>TG Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>TG Therapeutics</strong> 警报：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师意见</h2>
</div><p>Several analysts recently issued reports on the stock. B. Riley raised shares of TG Therapeutics to a &#34;strong-buy&#34; rating in a research note on Tuesday, November 4th. Wall Street Zen upgraded TG Therapeutics from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Sunday. HC Wainwright assumed coverage on TG Therapeutics in a report on Monday, October 6th. They issued a &#34;buy&#34; rating and a $60.00 price target for the company. JPMorgan Chase &amp; Co. boosted their price objective on TG Therapeutics from $46.00 to $49.00 and gave the stock an &#34;overweight&#34; rating in a research note on Monday, November 3rd. Finally, Weiss Ratings restated a &#34;hold (c+)&#34; rating on shares of TG Therapeutics in a report on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, TG Therapeutics currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $50.25.</p>
<div class="lb-trans"><p>几位分析师最近对该股票发布了报告。B. Riley 在 11 月 4 日的研究报告中将 TG Therapeutics 的股票评级提高至 &#34;强力买入&#34;。Wall Street Zen 在周日的研究报告中将 TG Therapeutics 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;。HC Wainwright 在 10 月 6 日的报告中开始覆盖 TG Therapeutics。他们对该公司发布了 &#34;买入&#34; 评级，并设定了 60.00 美元的目标价。摩根大通将 TG Therapeutics 的目标价从 46.00 美元上调至 49.00 美元，并在 11 月 3 日的研究报告中给予该股票 &#34;超配&#34; 评级。最后，Weiss Ratings 在 12 月 8 日的报告中重申了对 TG Therapeutics 股票的 &#34;持有 (c+)&#34; 评级。一位股票研究分析师对该股票给予了强力买入评级，两位给予了买入评级，两位给予了持有评级。根据 MarketBeat.com 的数据，TG Therapeutics 当前的平均评级为 &#34;适度买入&#34;，共识目标价为 50.25 美元。</p>
</div><ul>
<li>TG Therapeutics Stock 300% Rally Has Legs Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>TG Therapeutics 股票 300% 的反弹还有潜力</li>
</ul>
</div><p><strong>Get Our Latest Analysis on TG Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们对 TG Therapeutics 的最新分析</strong></p>
</div><h2>Insider Transactions at TG Therapeutics</h2>
<div class="lb-trans"><h2>TG Therapeutics 的内部交易</h2>
</div><p>In other TG Therapeutics news, Director Yann Echelard sold 5,000 shares of the company's stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $32.57, for a total value of $162,850.00. Following the transaction, the director owned 223,816 shares of the company's stock, valued at $7,289,687.12. This represents a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 10.64% of the company's stock.</p>
<div class="lb-trans"><p>在其他 TG Therapeutics 的新闻中，董事 Yann Echelard 在 11 月 24 日的交易中出售了 5,000 股公司的股票。该股票以平均价格 32.57 美元出售，总价值为 162,850.00 美元。交易后，该董事持有 223,816 股公司的股票，价值 7,289,687.12 美元。这代表了他们持有股票的比例下降了 2.19%。该交易已在向 SEC 提交的文件中披露，文件可通过此链接获取。公司内部人士持有公司股票的 10.64%。</p>
</div><h2>TG Therapeutics Trading Down 2.0%</h2>
<div class="lb-trans"><h2>TG Therapeutics 股票下跌 2.0%</h2>
</div><p>TGTX opened at $31.35 on Friday. The stock has a market capitalization of $4.98 billion, a PE ratio of 11.28 and a beta of 2.01. TG Therapeutics, Inc. has a one year low of $25.28 and a one year high of $46.48. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.89 and a current ratio of 3.82. The business's 50 day moving average price is $32.91 and its 200 day moving average price is $33.67.</p>
<div class="lb-trans"><p>TGTX 周五开盘价为 31.35 美元。该股票的市值为 49.8 亿美元，市盈率为 11.28，贝塔值为 2.01。TG Therapeutics, Inc. 的一年最低价为 25.28 美元，一年最高价为 46.48 美元。该公司的债务与股本比率为 0.40，速动比率为 2.89，流动比率为 3.82。该公司的 50 日移动平均价格为 32.91 美元，200 日移动平均价格为 33.67 美元。</p>
</div><p>TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, beating analysts' consensus estimates of $0.24 by $2.19. TG Therapeutics had a return on equity of 133.24% and a net margin of 84.13%.The company had revenue of $161.71 million for the quarter, compared to the consensus estimate of $152.12 million. During the same quarter in the previous year, the business earned $0.02 earnings per share. The company's revenue for the quarter was up 92.7% on a year-over-year basis. As a group, equities research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.</p>
<div class="lb-trans"><p>TG Therapeutics (NASDAQ:TGTX - 获取免费报告) 最近在 11 月 3 日发布了其财报。这家生物制药公司报告本季度每股收益为 2.43 美元，超出分析师共识预期的 0.24 美元，超出幅度为 2.19 美元。TG Therapeutics 的股本回报率为 133.24%，净利润率为 84.13%。该公司本季度的收入为 1.6171 亿美元，而共识预期为 1.5212 亿美元。在去年同期，该公司的每股收益为 0.02 美元。该公司的季度收入同比增长 92.7%。作为一个整体，股票研究分析师预计 TG Therapeutics, Inc. 本年度将发布 0.08 美元的每股收益。</p>
</div><h2>TG Therapeutics Profile</h2>
<div class="lb-trans"><h2>TG Therapeutics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.</p>
<div class="lb-trans"><p>TG Therapeutics, Inc. 是一家商业阶段的生物制药公司，专注于在美国和国际上获取、开发和商业化针对 B 细胞介导疾病的新疗法。它提供 BRIUMVI，一种抗 CD20 单克隆抗体，用于治疗成人复发性多发性硬化症 (RMS) 患者，包括临床孤立综合症、复发 - 缓解型疾病和活动性继发进展型疾病的成人患者。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than TG Therapeutics</li>
<li>What Are Dividend Achievers? An Introduction</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
<li>5 discounted opportunities for dividend growth investors</li>
<li>Why Amazon Could Be a $300 Stock Within Weeks</li>
<li>How to Profit From Value Investing</li>
<li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 TG Therapeutics</li>
<li>什么是分红成就者？简介</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
<li>5 个适合分红增长投资者的折扣机会</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>如何从价值投资中获利</li>
<li>Adobe 在财报后获得提振：长期前景看涨</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TGTX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有 TGTX 吗？</strong> 访问 HoldingsChannel.com 获取 TG Therapeutics, Inc. (NASDAQ:TGTX - 免费报告) 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEdUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TGTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in TG Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 TG Therapeutics 吗？</h2>
</div><p>Before you consider TG Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 TG Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议他们现在购买，以便在更广泛的市场注意到之前……而 TG Therapeutics 并不在名单上。</p>
</div><p>While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 TG Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Marex Group plc 新增投资 1002 万美元于 TG Therapeutics, Inc.（股票代码：TGTX）